Project Details
Description
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects with Alopecia Areata
| Status | Active |
|---|---|
| Effective start/end date | 12/9/21 → 12/31/26 |
Funding
- ANAPTYSBIO, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.